Lung scarring may alter immunotherapy success in cancer patients
NCT ID NCT07396467
First seen Feb 10, 2026 · Last updated May 13, 2026 · Updated 9 times
Summary
This study examines how well immunotherapy works in people who have both lung cancer and pulmonary fibrosis (lung scarring). Researchers will review medical records of 200 patients and analyze tumor tissue at a cellular level to understand why some respond differently. The goal is to improve treatment decisions for this complex group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029, China
Conditions
Explore the condition pages connected to this study.